New generation direct oral anticoagulants effects on thrombotic events prevention after atrial fibrillation.
This study aimed to assess the efficacy of novel direct oral anticoagulants (DOACs) in preventing thrombotic events following atrial fibrillation (AF) within the Uzbek patient demographic. Conducted as a prospective, multicenter cohort study, it involved 500 patients diagnosed with non-valvular AF f...
| Publicado en: | Revista Latinoamericana de Hipertensión Vol. 20; no. 4; pp. 254 - 261 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artículo |
| Publicado: |
Revista Latinoamericana de Hipertension
2025
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=185581256&site=ehost-live header: @attributes: shortDbName: lth uiTerm: 185581256 longDbName: MedicLatina uiTag: AN controlInfo: bkinfo: jinfo: jid: 18564550 FICN jtl: Revista Latinoamericana de Hipertensión issn: 18564550 maglogo: N pubinfo: dt: 2025 vid: 20 iid: 4 pid: 81901 pub: Revista Latinoamericana de Hipertension artinfo: ui: 185581256 10.5281/zenodo.15358159 ppf: 254 ppct: 7 formats: fmt: @attributes: type: P size: 981KB tig: atl: New generation direct oral anticoagulants effects on thrombotic events prevention after atrial fibrillation. aug: au: Sultonovna, Ergasheva Yulduz Esanmurodova, N. Gulnoza, Rustamova Diyorbek, Yoqubov Eshchanova, Nasiba Ilkhom, Abdurakhmonov Umarjanovich, Satvaldiyev Ixtiyarjon affil: Assistant of the Department of Propaedeutics of children diseases and child neurology, Bukhara State Medical Institute Named After Abu Ali Ibn Sino, 200100 Bukhara, Uzbekistan "Tashkent Institute of Irrigation and Agricultural Mechanization Engineers" National Research University, Tashkent, Uzbekistan Baku Eurasian University, Baku, AZ 1073, Azerbaijan Associate Professor, Samarkand State Medical University, 140100 Samarkand, Uzbekistan Teacher of the Department of Fruits and Vegetables, Urgench State University, Uzbekistan Department of Psychological Sciences, Mamun university, Khiva, Uzbekistan Department of Propaedeutics of Children's Diseases and Outpatient Pediatrics, Andijan State Medical Institute, Uzbekistan Department of Dentistry and Otorhinolaryngology, Fergana Medical Institute of Public Health, Fergana, Uzbekistan su: Oral medication Anticoagulants Ischemic stroke Warfarin Dabigatran Apixaban Atrial fibrillation Uzbekistan sug: subj: Uzbekistan Oral medication Anticoagulants Ischemic stroke Warfarin Dabigatran Apixaban Atrial fibrillation keyword: atrial fibrillation Novel oral anticoagulants prevention of thrombosis thrombotic events Uzbek population eventos trombóticos fibrilación auricular Nuevos anticoagulantes orales población uzbeka prevención de trombosis ab: This study aimed to assess the efficacy of novel direct oral anticoagulants (DOACs) in preventing thrombotic events following atrial fibrillation (AF) within the Uzbek patient demographic. Conducted as a prospective, multicenter cohort study, it involved 500 patients diagnosed with non-valvular AF from 2022 to 2024. Participants were categorized into two groups: one receiving DOACs (apixaban, rivaroxaban, and dabigatran) and a control group treated with warfarin, with follow-up extending over 18 months. The findings revealed that the administration of DOACs led to a notable decrease in the occurrence of thrombotic events, such as ischemic stroke and systemic embolism (hazard ratio [HR]: 0.65; 95% confidence interval: 0.52-0.81; P < 0.001). Furthermore, the incidence of major bleeding was significantly lower in the DOAC group compared to the warfarin group (3.2% versus 7.8%; P = 0.02). Sub-analyses highlighted improved adherence to DOACs, attributed to the absence of the need for regular INR monitoring. This research supports the notion that new-generation anticoagulants, which demonstrate enhanced efficacy and a favorable safety profile, represent an optimal treatment choice for managing AF patients in the Uzbek population. Este estudio tuvo como objetivo evaluar la eficacia de los nuevos anticoagulantes orales directos (ACOD) en la prevención de eventos trombóticos tras la fibrilación auricular (FA) en pacientes uzbekos. Se realizó como un estudio de cohorte prospectivo y multicéntrico, en el que participaron 500 pacientes con diagnóstico de FA no valvular entre 2022 y 2024. Los participantes se dividieron en dos grupos: uno que recibió ACOD (apixabán, rivaroxabán y dabigatrán) y un grupo control tratado con warfarina, con un seguimiento de 18 meses. Los hallazgos revelaron que la administración de ACOD condujo a una disminución notable en la incidencia de eventos trombóticos, como ictus isquémico y embolia sistémica (cociente de riesgo [HR]: 0,65; intervalo de confianza del 95 %: 0,52-0,81; p < 0,001). Además, la incidencia de hemorragia mayor fue significativamente menor en el grupo de ACOD que en el grupo de warfarina (3,2 % frente a 7,8 %; p = 0,02). Los subanálisis destacaron una mejor adherencia al tratamiento con ACOD, atribuida a la ausencia de la necesidad de monitorización regular del INR. Esta investigación respalda la idea de que los anticoagulantes de nueva generación, que demuestran una mayor eficacia y un perfil de seguridad favorable, representan una opción terapéutica óptima para el manejo de pacientes con FA en la población uzbeka. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: Y custom: Copyright of Revista Latinoamericana de Hipertensión is the property of Revista Latinoamericana de Hipertension and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. item: Revista Latinoamericana de Hipertensión holder: Revista Latinoamericana de Hipertension dt: @attributes: year: 2025 holdings: @attributes: islocal: N |
|---|